CFD RESEARCH CORPORATION SBIR Phase II Award, May 2023

A SBIR Phase II contract was awarded to CFD Research Corporation in May, 2023 for $548,493.0 USD from the U.S. Department of Defense and Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.

Overview Structured Data Issues Contributors Activity

sbir.gov/node/2579407

Is a

SBIR/STTR Awards

SBIR/STTR Award attributes

SBIR/STTR Award Recipient

CFD Research Corporation

Government Agency

U.S. Department of Defense

Government Branch

Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense

Award Type

SBIR0

Contract Number (US Government)

W911SR-23-C-00140

Award Phase

Phase II0

Award Amount (USD)

548,4930

Date Awarded

May 15, 2023

End Date

May 18, 2025

Abstract

This project seeks to develop a new broad-spectrum antiviral drug against viruses from the Bunyavirales family. These viruses have been designated as being among the highest potential to cause the next pandemic. CFD Research is advancing a natural product-derived antiviral chemistry that has demonstrated strong in vitro potency against Bunyaviruses with low cytotoxicity. We seek to produce an optimized lead candidate from this project.